$NASDAQ%3AIBB

Pharming Group N.V. reported its Q4 2025 earnings, showcasing significant growth in revenue driven by increased demand for its flagship drug, Ruconest. The company announced a strategic partnership which is expected to accelerate research and development in their pipeline. Despite a quarterly loss, the management remains optimistic about future profitability and market expansion. Analysts are closely monitoring the performance of Ruconest and upcoming product launches. Overall, the earnings call highlighted a promising trajectory for Pharming Group moving into 2026.